Lilly Halts Add-On Depression Treatment After Disappointing Studies

Eli Lilly said it wouldn't further develop its edivoxetine depression treatment after it didn't meet the primary endpoint in Phase III clinical studies.



from WSJ.com: US Business http://online.wsj.com/article/SB10001424052702303997604579239842139146898.html?mod=pls_whats_news_us_business_f

via IFTTT